Education, Science, Technology, Innovation and Life
Open Access
Sign In

Research progress of proteomics in screening tumor markers of gastric cancer

Download as PDF

DOI: 10.23977/medsc.2022.030702 | Downloads: 16 | Views: 666

Author(s)

Dongkai Wu 1, Chen Ling 1, Qiang Zhao 2

Affiliation(s)

1 Changzhi Medical College, Changzhi, Shanxi, 046000, China
2 Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, 046000, China

Corresponding Author

Qiang Zhao

ABSTRACT

Gastric cancer is a significant disease that endangers human life and health, ranking 3rd in the spectrum of disease incidence and death in China. It is mostly locally progressive and advanced, with fewer early-stage patients and an overall survival rate and quality of survival significantly lower than abroad. Now, early diagnosis and treatment, extending the survival time, and improving the quality of survival have become hot spots in treating gastric cancer. Protein is the performer of life activities. The protein of gastric cancer is different from that of healthy people. The understanding of its protein will be of great significance for disease prevention, diagnosis, and treatment, but the latest research reports are few; This article reviews the Progress of proteomics in screening tumor markers of gastric cancer.

KEYWORDS

Gastric cancer, proteomics technology, protein interactions, tumor markers

CITE THIS PAPER

Dongkai Wu, Chen Ling, Qiang Zhao, Research progress of proteomics in screening tumor markers of gastric cancer. MEDS Clinical Medicine (2022) Vol. 3: 7-14. DOI: http://dx.doi.org/10.23977/medsc.2022.030702.

REFERENCES

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May; 71(3):209-249.
[2] Li M, Peng F, Wang G, et al. Coupling of cell surface biotinylation and SILAC- based quantitative proteomics identified myoferlin as a potential therapeutic target for nasopharyngeal carcinoma metastasis[J]. Front Cell Dev Biol, 2021, 9: 621810.
[3] Zhang Q, Lou Y, Yang J, et al. Integrated multi-omic analysis reveals comprehensive tumor heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas [J]. Gut, 2019: 1-13.
[4] Yang Z Z, Kim H J, Villas Boas J C, et al. Mass cytometry analysis reveals that specific intratumoral cd4 (+)t cell subsets correlate with patient survival in follicular lymphoma[J]. Cell Reports, 2019, 26(8): 2178.
[5] Blair T A, Michelson A D, Frelinger A L. Mass cytometry reveals distinct platelet subtypes in healthy subjects and novel alterations in surface glycoproteins in Glanzman thrombasthenia [J]. Scientific Reports, 2018,8:10300.
[6] Mistry A M, Green Plate A R, Ihrie R A, et al. Beyond the message: advantages of snapshot proteomics with single-cell mass cytometry in solid tumors [J]. Feb J, 2019, 286(8):1523-1539.
[7] Chang J and Kim Y and Kwon H J. Advance in identification and validation of protein targets of natural products without chemical modification. [J]. Natural product reports, 2016, 33(5): 719-30.
[8] Aslam B, BASIT M, NISAR M A, et al. Proteomics: technologies and their applications[J]. J Chromatogr Sci, 2017, 55 (2): 182-196.
[9] Yi Huang, Heng Zhu. Protein Array-based Approaches for Biomarker Discovery in Cancer[J]. Genomics Proteomics Bioinformatics, 2017, 15(2): 73-81 .
[10] Ventzislava A Hristova, Daniel W Chan. Chan. Cancer biomarker discovery and translation: proteomics and beyond [J]. Expert Review of Proteomics, 2019, 16(2): 93-103. 
[11] Stewart CL, Chojnowski A, Sobota R M, et al. 2C -BioID: An advanced two-component BioID system for precision mapping of protein interactomes [J]. iScience, 2018, 10: 40-52.
[12] Lian G, Li L, Ye F, Wang D, Liu J, Shi Y, Jing C, Suo J, Zhang DY, Chen M. The screening and analysis of protein signatures and signaling associated with chemoresistance based on Protein Pathway Array technology in gastric cancer. Oncol Rep. 2018 Jan; 39(1):307-315. 
[13] Ni X, Tan Z, Ding C, Zhang C, Song L, Yang S, Liu M, Jia R, Zhao C, Song L, Liu W, Zhou Q, Gong T, Li X, Tai Y, Zhu W, Shi T, Wang Y, Xu J, Zhen B, Qin J. A region-resolved mucosa proteome of the human stomach. Nat Commun. 2019 Jan 3; 10(1):39. 
[14] Li X, Zheng NR, Wang LH, Li ZW, Liu ZC, Fan H, Wang Y, Dai J, Ni XT, Wei X, Liu MW, Li K, Li ZX, Zhou T, Zhang Y, Zhang JY, Kadeerhan G, Huang S, Wu WH, Liu WD, Wu XZ, Zhang LF, Xu JM, Gerhard M, You WC, Pan KF, Li WQ, Qin J. Proteomic profiling identifies signatures associated with progression of precancerous gastric lesions and risk of early gastric cancer. EBio Medicine. 2021 Dec; 74:103714. 
[15] Yuan X, Xiao Y, Luo Y, Wei C, Wang J, Huang J, Liao W, Song S, Jiang Z. Identification and validation of PGLS as a metabolic target for early screening and prognostic monitoring of gastric cancer. J Clin Lab Anal. 2022 Feb; 36(2):e24189. 
[16] Krebsbach GM, Pawlak M. High Precision RPPA: Concept, Features, and Application Performance of the Integrated Zeptosens Platform [J]. Adv Exp Med Biol, 2019,1188: 31-59.
[17] Shen Q, Polom K, Williams C, de Oliveira FMS, Guergova-Kuras M, Lysacek F, Karlsson NG, Roviello F, Kamali-Moghaddam M. A targeted proteomics approach reveals a serum protein signature as diagnostic biomarker for resectable gastric cancer. EBioMedicine. 2019 Jun; 44:322-333. 
[18] Shen J, Zhai J, Wu X, Xie G, Shen L. Serum proteome profiling reveals SOX3 as a candidate prognostic marker for gastric cancer. J Cell Mol Med. 2020 Jun;24(12):6750-6761. 
[19] Liu ZC, Wu WH, Huang S, Li ZW, Li X, Shui GH, Lam SM, Li BW, Li ZX, Zhang Y, Zhou T, You WC, Pan KF, Li WQ. Plasma lipids signify the progression of precancerous gastric lesions to gastric cancer: a prospective targeted lipidomics study. Theranostics. 2022 Jun 6; 12(10):4671-4683. 
[20] Aziz S, Rasheed F, Zahra R, König S. Gastric Cancer Pre-Stage Detection and Early Diagnosis of Gastritis Using Serum Protein Signatures. Molecules. 2022 Apr 30; 27(9):2857. 
[21] Jin J, Son M, Kim H, Kim H, Kong SH, Kim HK, Kim Y, Han D. Comparative proteomic analysis of human malignant ascitic fluids for the development of gastric cancer biomarkers. Clin Biochem. 2018 Jun; 56:55-61. 
[22] Huang L, Xu A. Detection of digestive malignancies and post-gastrectomy complications via gastrointestinal fluid examination. Front Med. 2017 Mar;11(1):20-31. 
[23] Shu J, Yu H, Li X, Zhang D, Liu X, Du H, Zhang J, Yang Z, Xie H, Li Z. Salivary glycopatterns as potential biomarkers for diagnosis of gastric cancer. Oncotarget. 2017 May 30; 8(22):35718-35727.
[24] Shimura T, Day D, Wang H, Okuda Y, Iwasaki H, Ebi M, Kitagawa M, Yamada T, Yamada T, Hanash SM, Taguchi A, Kataoka H. Novel urinary protein biomarker panel for early diagnosis of gastric cancer. Br J Cancer. 2020 Nov; 123(11):1656-1664. 
[25] Yang JS, Kang CY, Su CH, Chen CJ, Chiu YJ, Hsu YM. Helicobacter pylori Targets in AGS Human Gastric Adenocarcinoma: In Situ Proteomic Profiling and Systematic Analysis. Anticancer Res. 2022 Jan;42(1):531-546. 
[26] Han S, Jiang X, Sun XF, Zhang H, Li C, Zhao Z, Yu W. Application value of CyTOF 2 mass cytometer technology at single-cell level in human gastric cancer cells. Exp Cell Res. 2019 Nov 1; 384(1):111568. 
[27] Lu J, Jiang H, Li D, Chen T, Wang Y, Pu Z, Xu G. Proximity Labeling, Quantitative Proteomics, and Biochemical Studies Revealed the Molecular Mechanism for the Inhibitory Effect of Indisulam on the Proliferation of Gastric Cancer Cells. J Proteome Res. 2021 Sep 3; 20(9):4462-4474. 
[28] Zoroaster M, Nasser R, Hage-Sleiman R, Abdel-Sater F, Badran B, Zeaiter Z. Helicobacter pylori outer membrane vesicles induce expression and secretion of oncostatin M in AGS gastric cancer cells. Braz J Microbiol. 2021 Sep; 52(3):1057-1066. 
[29] Song L, Song M, Rabkin CS, Williams S, Chung Y, Van Duine J, Liao LM, Karthikeyan K, Gao W, Park JG, Tang Y, Lissowska J, Qiu J, LaBaer J, Camargo MC. Helicobacter pylori Immunoproteomic Profiles in Gastric Cancer. J Proteome Res. 2021 Jan 1; 20(1):409-419. 
[30] Koizumi Y, Ahmad S, Ikeda M, Yashima-Abo A, Espina G, Sugimoto R, Sugai T, Iwaya T, Tamura G, Koeda K, Liotta LA, Takahashi F, Nishizuka SS; Northern Japan Gastric Cancer Study Consortium. Helicobacter pylori Modulated Host Immunity in Gastric Cancer Patients With S-1 Adjuvant Chemotherapy. J Natl Cancer Inst. 2022 Aug 8; 114(8):1149-1158. 
[31] Ge S, Xia X, Ding C, Zhen B, Zhou Q, Feng J, Yuan J, Chen R, Li Y, Ge Z, Ji J, Zhang L, Wang J, Li Z, Lai Y, Hu Y, Li Y, Li Y, Gao J, Chen L, Xu J, Zhang C, Jung SY, Choi JM, Jain A, Liu M, Song L, Liu W, Guo G, Gong T, Huang Y, Qiu Y, Huang W, Shi T, Zhu W, Wang Y, He F, Shen L, Qin J. A proteomic landscape of diffuse-type gastric cancer. Nat Commun. 2018 Mar 8; 9(1):1012.

Downloads: 5189
Visits: 241540

Sponsors, Associates, and Links


All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.